 |
|||
  
|
|
||
 |
|||
| The Principals have made investments in the following pharmaceutical companies: | |||
|
|||
|
|||
 |
|||
| Cerus Corporation (ticker: CERS)
| www.cerus.com | is marketing and
developing systems to inactivate viruses, bacteria and other pathogens in
blood components for transfusion. The company also is focused on developing
new vaccine technologies. |
|||
|
|
|||
Clarus Therapeutics, Inc. | www.clarustherapeutics.com | is developing new approaches for hormone replacement therapy. |
|||
 |
|||
The Medicines Company (ticker: MDCO) | www.themedicinescompany.com | is a licensing-focused, drug development company currently marketing Angiomax™, a novel anti-coagulant.
|
|||
 |
|||
NeuroTherapeutics Pharma, Inc. | www.neurotherapeuticspharma.com | is an early stage company focused on the development of therapies for CNS disorders, with an initial focus on epilepsy.
|
|||
|
|||
Ocera Therapeutics, Inc. | www.oceratherapeutics.com | is focused on the development of pharmaceutical products for gastrointestinal and liver diseases.
|
|||
 |
|||
Oriel Therapeutics is a respiratory drug delivery company developing dry powder delivery systems for the treatment of asthma and COPD.
|
|||
|
|||
Quinnova Pharmaceuticals, Inc. | www.quinnova.com | is a specialty pharmaceutical company focused on the development and commercialization of prescription drug products based on innovative drug delivery platforms for the dermatology market. |
|||
|
|||
Solstice Neurosciences, Inc. | www.solsticeneuro.com | manufactures and markets Myobloc™, an FDA approved formulation of Botulinum Toxin type B, for the treatment of neurologically-induced muscle spasms.
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
| Zogenix, Inc. | www.zogenix.com | is a specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain, with an initial focus on Intraject® sumatriptan, a needle-free migraine treatment. | |||
|
|
|
|
|
